Cytokinetics CYTK
United StatesHealthcare · BiotechnologyUSD
109.90 USD (+79.8%)
20 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Cytokinetics is a clinical-stage biopharmaceutical company developing innovative therapies for cardiovascular diseases, with no approved products on the market and financing its operations through equity and debt issuances.
Key points
from its scores- ✓Favourable backdrop8.1
- ✕Weak growth0.0
- ✕Demanding valuation0.5
- ✕Little competitive advantage1.0
AI analysis
bottom line, main risk, context and newsThe company has no approved products, burns cash at an unsustainable rate, and its valuation discounts a clinical success that has not yet materialized.
Cytokinetics presents a high-risk profile: no product sales, an operating margin of -625.95%, and revenue growth of -57.10%, reflecting a pre-commercial stage with intense cash burn. Its valuation (FCF yield of -4.68) and quality (score 1.0) are very weak, and the rising rate environment adds pressure on its future financing capacity.
The main risk is clinical and regulatory execution: failure of a Phase 3 trial or an FDA rejection could destroy most of the company's value, given it has no revenue to support it.
Context and risks
Cytokinetics is a clinical-stage biotech with no product sales and an operating margin of -625.95%, making it highly dependent on capital markets to fund its trials. Tightening financial conditions (rising long-term rates) make access to financing more expensive for companies without cash generation, a material risk to its business model.
Is Cytokinetics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 3,574% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / sales | 125.6 | 3.4 | +3,574% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 109.90 USD, +79.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 1.0 (sector 5.5), Growth 0.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −13.7
- EV / EBITDA
- −12.6
- Price / book
- −48.9
- Price / sales
- 125.6
- Market cap
- 8.5B USD
- Enterprise value
- 8.8B USD
Profitability
- ROA
- −28.1%
- Gross margin
- 0.0%
- Operating margin
- −626.0%
- Net margin
- 0.0%
- Free cash flow
- −397.4M USD
- FCF yield
- −4.7%
Solvency
- Total debt
- 1.4B USD
- Net debt
- 258.8M USD
- Cash
- 1.2B USD
- EBITDA
- −695.4M USD
- Net debt / EBITDA
- −0.37
- Current ratio
- 6.66
- Quick ratio
- 6.56
Growth
- Revenue growth
- −57.1%
- EPS (TTM)
- −7.22 USD
- EPS (forward)
- −4.45 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.41
- Analyst consensus
- Strong buy (20)
- Target price
- 109.90 USD
- 52-week range
- 54.30 – 88.31
Recent news
All CYTK news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Cytokinetics
Is Cytokinetics stock cheap or expensive?
On Price / sales, it trades 3,574% above the Healthcare median. Valuation score: 0.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 109.90 USD, +79.8% versus the price. This is not investment advice.
What score does Cytokinetics get on MeridIAn Screener?
It scores 2.8 out of 10, rank 2,096 of 2,130 (better than 2% of the companies analysed). Its strongest category is Risk & Context (8.1) and its weakest, Growth (0.0). Analysis of 08/10/2026.
How much is Cytokinetics worth on the stock market?
Its market capitalisation is 8.5B USD and its enterprise value, debt included, is 8.8B USD.
How much debt does Cytokinetics have?
Its net debt (debt minus cash) is 258.8M USD.
Does Cytokinetics pay a dividend?
It pays no dividend, or almost none.
How has Cytokinetics stock performed over the last year?
It has risen 1.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 54.30 and 88.31 USD. Past performance does not guarantee future results.
What do analysts think of Cytokinetics?
20 analysts cover it; their average recommendation is “Strong buy” and their average target is 109.90 USD (+79.8% versus the price). It is an estimate, not market data.